CONTACT: CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, defendants' positive statements about the Company' ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price, dropping approximately 38% from $26.12 to $16.21 per share on April 3, 2025, after cutting its 2025 revenue forecast due to a market softening noted in the second half of 2024 [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share on July 9, 2025 [6].

Core Points - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit for shareholders who purchased shares during the specified class period [1] - The class period is defined as November 7, 2024, to July 8, 2025, during which the company allegedly made materially false and misleading statements about its business performance [3] - Allegations include that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization, overstated demand for its products, and an inability to meet previously issued financial guidance for fiscal year 2025 [3] Shareholder Information - Shareholders are encouraged to register for the class action by the deadline of September 22, 2025, to potentially become lead plaintiffs [4] - Registration allows shareholders to receive updates through a portfolio monitoring software regarding the status of the case [4] - Participation in the case incurs no cost or obligation for shareholders [4] Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5]

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified Class Period [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery [2]. Legal Allegations - The lawsuit alleges that RxSight failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the decline to adoption challenges [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the financial results and guidance revision led to a nearly 38% drop in RxSight's stock price [5].

NEW YORK, Aug. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of RxSight, Inc. (NASDAQ: RXST).Shareholders who purchased shares of RXST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/rxsight-inc-loss-submission-form/?id=159228&from=4CLASS PERIOD: November 7, 2024 to July 8, ...

ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. “We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors,” said J. Andy Corley, Chairman of the Board at RxSight. “Ray’s extensive track record in leading and scaling medical technology compani ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities, with the case pending in the U.S. District Court for the Central District of California [2]. - The company allegedly failed to disclose "adoption challenges" for its products, despite promoting strong sales figures, leading to a slowdown in LAL utilization first noted in 2024 [4]. Group 3: Stock Performance - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, resulting in a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of their potential entitlement to compensation through a class action lawsuit [1][4]. Group 1: Class Action Details - The Class Period for the RxSight securities is from November 7, 2024, to July 8, 2025, and the lead plaintiff deadline is September 22, 2025 [1][2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. Group 2: Allegations Against RxSight - The lawsuit alleges that RxSight made false and misleading statements regarding its business performance, including issues with product adoption and overstated demand [4]. - It is claimed that RxSight was unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. - The misleading statements led to investor damages when the true situation was revealed [4].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the financial results led to a nearly 38% drop in the price of RxSight stock [5].